Investigation of Some Metabolic Enzyme Inhibition Properties of Novel Chalcone-Cu Complexes

Basit Öğe Kaydı
dc.contributor.authorEbiri, Rustem
dc.contributor.authorTurgut, Muhammet
dc.contributor.authorAnil, Derya Aktas
dc.contributor.authorDemir, Yeliz
dc.contributor.authorSaglamtas, Ruya
dc.contributor.authorAlagoz, M. Abdullah
dc.contributor.authorAlgul, Oztekin
dc.date.accessioned2024-08-04T20:56:12Z
dc.date.available2024-08-04T20:56:12Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractFourteen novel Chalcone-Cu complexes were effectively synthesized in this work. The newly synthesized Chalcone-Cu complexes were assessed for their effects on human carbonic anhydrase isoenzymes I and II, acetylcholinesterase enzymes, and antioxidant activity. The intricate compounds exhibited Ki values ranging from 41.65-190.42 nM against hCA I, 15.79-259.07 nM against hCA II, and 14.36-175.73 nM against AChE enzymes. These complexes demonstrated potent inhibitory profiles against the specified metabolic enzymes, surpassing the inhibitory effects of acetazolamide (for hCA I and II) and tacrine (for AChE). The antioxidant properties of the compounds were assessed using DPPH and ABTS radical scavenging assays, revealing that the complexes had moderate to high efficacy in neutralizing free radicals. All complexes underwent molecular docking experiments. Compounds 14, 22, and 23 yielded the highest docking scores. Compound 14 demonstrated a docking score of -6.414 kcal/mol against hCAI, whereas compound 23 attained a docking score of -6.697 kcal/mol against hCA II. Compound 22 exhibited the most favorable docking score of -9.645 kcal/mol against AChE. The acquired results have the potential to help towards the development of new drugs containing Cu complex structures for the treatment of prevalent ailments such as glaucoma and Alzheimer's diseases. This study unveils the potential of Chalcone-Cu complexes as potent enzyme inhibitors (hCA I and II and AChE) with antioxidant properties. The structural insights, inhibitory profiles, and molecular docking results underscore their therapeutic potential for neurological disorders. The findings present a foundation for further exploration and drug development in the realm of Chalcone-Cu compounds. imageen_US
dc.identifier.doi10.1002/slct.202401093
dc.identifier.issn2365-6549
dc.identifier.issue27en_US
dc.identifier.scopus2-s2.0-85198476823en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1002/slct.202401093
dc.identifier.urihttps://hdl.handle.net/11616/102118
dc.identifier.volume9en_US
dc.identifier.wosWOS:001269313600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWiley-V C H Verlag Gmbhen_US
dc.relation.ispartofChemistryselecten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChalcone-Cu complexesen_US
dc.subjectAChEen_US
dc.subjecthCA I and hCA IIen_US
dc.subjectAntioxidant activityen_US
dc.subjectMolecular dockingen_US
dc.titleInvestigation of Some Metabolic Enzyme Inhibition Properties of Novel Chalcone-Cu Complexesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu